﻿<?xml version='1.0' encoding='UTF-8'?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>Arthritis Foundation Forum / RA Connect / Rheumatoid Arthritis - (RA Connect)  / Long-term methotrexate appears safe in arthritis / Latest Posts</title><generator>InstantForum.NET v4.1.4</generator><description>Arthritis Foundation Forum</description><link>http://community.arthritis.org/forums/</link><webMaster>sitehelp@arthritis.org</webMaster><lastBuildDate>Sun, 22 Nov 2009 00:47:52 GMT</lastBuildDate><ttl>20</ttl><item><title>RE: Long-term methotrexate appears safe in arthritis</title><link>http://community.arthritis.org/forums/Topic4214189-1831-1.aspx</link><description>&lt;FONT size=3&gt;I'm not sure if there is an official definition of "long term" but I think anything over a year is long term.  Medications for most conditions are used for a few weeks or months but RA is a chronic condition and usually requires lifelong treatment.  God bless.&lt;/FONT&gt;</description><pubDate>Sat, 04 Jul 2009 00:17:56 GMT</pubDate><dc:creator>Grandpavan</dc:creator></item><item><title>RE: Long-term methotrexate appears safe in arthritis</title><link>http://community.arthritis.org/forums/Topic4214189-1831-1.aspx</link><description>OK, I'm new, so this may be a silly question - but they mention long-term treatment with MTX and then state 2 years or longer.  Is 2 years on this drug considered "long-term"? &lt;/P&gt;&lt;P&gt;Donna</description><pubDate>Fri, 03 Jul 2009 17:32:09 GMT</pubDate><dc:creator>DonnaT</dc:creator></item><item><title>Long-term methotrexate appears safe in arthritis</title><link>http://community.arthritis.org/forums/Topic4214189-1831-1.aspx</link><description>&lt;FONT face=Arial&gt; &lt;/FONT&gt;&lt;P class=headline&gt;&lt;P class=datestamp&gt;&lt;SMALL&gt;&lt;EM&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/SMALL&gt;&lt;/P&gt;&lt;FONT color=#991111 size=3&gt;NEW YORK (Reuters Health) - In adults who suffer from rheumatoid arthritis (RA), long-term treatment with methotrexate (MTX) appears safe, according to pooled data from 88 studies of patients with RA treated with only MTX for at least 2 years. &lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;"Overall, although many patients experience adverse events during MTX treatment, they are generally mild and withdrawals of MTX for toxicity are less common than for other disease-modifying anti-rheumatic drugs," Dr. C. Salliot of Hopital Cochin in Paris, France and Dr. D. van der Heijde of Leiden University Medical Center in The Netherlands conclude. &lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;Over 12 years of treatment, the termination rate of MTX due to toxicity was less than for other commonly prescribed arthritis drugs such as sulfasalazine, gold, and D-penicillamine but higher than for hydrochloroquine, the researchers found. &lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;Thirteen percent of patients taking MTX experienced potentially harmful spikes in liver enzymes, but only 3.7% discontinued MTX due to liver toxicity. &lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;Data on risk of liver scarring or "fibrosis" with long-term MTX use were inconclusive. One study found a 2.7% rate of liver scarring in patients who took MTX for 4 years, but no evidence of liver damage in two other studies in which patients had repeated liver biopsies.&lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;Long-term MTX did not appear to increase patients' risk for infections in general or for serious infections, including herpes zoster and infectious complications of joint replacement surgery.&lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;Of two studies that estimated patients' risk of cardiovascular diseases during treatment, one concluded that MTX was not a risk factor and the other "even found a reduced risk" for treated patients compared to RA patients who had never received MTX, sulfasalazine, or hydrochloroquine. In fact, the researchers said, it's possible that MTX "could provide a survival benefit by reducing cardiovascular mortality."&lt;/FONT&gt;&lt;/P&gt;&lt;P&gt;&lt;FONT color=#991111 size=3&gt;There were not enough data to determine whether long-term MTX therapy increases patients' risk of lymphoma and other malignancies, according to the authors. They add, however, that "there is no strong evidence of increased risk."&lt;/FONT&gt;&lt;/P&gt;&lt;P class=source&gt;&lt;FONT color=#991111 size=3&gt;SOURCE: Annals of the Rheumatic Diseases, June 2009. &lt;/FONT&gt;</description><pubDate>Fri, 03 Jul 2009 15:47:32 GMT</pubDate><dc:creator>Nikki Lynn</dc:creator></item></channel></rss>